SCHEMBL526271

SCHEMBL526271

CCOC(=O)c1onc2c1C(C)(C)CCC2=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
CACNA1F O60840 5/20 0.33
CACNA1D Q01668 5/20 0.33
CACNA1S Q13698 5/20 0.33
CACNA1C Q13936 5/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
KDM4E B2RXH2 3/20 0.33
TDP2 O95551 2/20 0.33
BRD4 O60885 1/20 0.33
ALOX15 P16050 2/20 0.32
GAA P10253 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP1A2 P05177 1/20 0.32
ABCB1 P08183 2/20 0.32
NPC1 O15118 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL526388 0.79 TDP2 (0.40) ALDH1A1MAPTLMNATP53CACNA1F
SCHEMBL12498389 0.75 BRD4 (0.45) ALDH1A1MAPTLMNATP53HPGD
SCHEMBL526385 0.75 BRD4 (0.48) ALDH1A1MAPTLMNATP53HPGD
SCHEMBL525552 0.74 CYP1A2 (0.40) ALDH1A1MAPTLMNAHPGDHSD17B10
SCHEMBL4159693 0.73 CCNA2 (0.46) ALDH1A1MAPTTP53HPGDHSD17B10
SCHEMBL526364 0.72 ALDH1A1 (0.37) ALDH1A1MAPTHPGDHSD17B10KDM4E
SCHEMBL4150053 0.71 POLB (0.42) ALDH1A1MAPTLMNAHPGDHSD17B10
SCHEMBL10650334 0.68 KDM4E (0.42) ALDH1A1MAPTLMNATP53HPGD
SCHEMBL20649054 0.67 ALDH1A1 (0.34) ALDH1A1MAPTHPGDHSD17B10KDM4E
SCHEMBL525742 0.66 MAPT (0.41) ALDH1A1MAPTCACNA1FCACNA1DCACNA1S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US disclosed
EP-2598508-B1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES SRL (IT) 2015-04-22 EP disclosed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US disclosed
EP-2598508-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY Nerviano Medical Sciences S.r.l. (IT) 2013-06-05 EP disclosed
WO-2012013557-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY CSNK1A1, RPS6KA1, CSNK2A1 ALDH1A1 3745/4885MAPT 2600/4885LMNA 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.